The European Medicines Agency (EMA) has given its recommendation for the approval of a groundbreaking medicine utilizing CRISPR/Cas9, an innovative gene-editing technology to modify the patient’s own blood stem cells. Known as Casgevy (exagamglogene autotemcel), this treatment is designed for individuals aged 12 and above suffering from transfusion-dependent beta thalassemia and severe sickle cell disease. It targets patients for whom traditional hematopoietic stem cell transplantation is suitable but a compatible donor is not available.

This revolutionary therapy holds the promise of liberating patients from the burdensome cycle of frequent transfusions and the excruciating vaso-occlusive crises associated with the blockage of small blood vessels by sickled red blood cells. Its introduction into medical practice has the potential to significantly enhance the quality of life for affected individuals.

Beta thalassemia and sickle cell disease are both rare hereditary disorders stemming from genetic mutations impacting the production or functionality of hemoglobin, the vital protein responsible for oxygen transport within red blood cells. These conditions entail lifelong challenges, posing significant threats to health and well-being.

Casgevy represents a cell-based gene therapy product leveraging CRISPR/Cas9 technology to modify the patient’s own blood stem cells. This personalized treatment, administered as a one-time intervention, involves the extraction of bone marrow stem cells from the patient’s bloodstream. CRISPR gene editing facilitates precise alterations to the genetic material within these cells, allowing for the addition, removal, or modification of specific sequences of DNA. In the case of Casgevy, the targeted editing occurs within the erythroid-specific enhancer region of the BCL11A gene, a locus known to suppress the production of fetal hemoglobin (HbF). By reducing BCL11A gene activity, the therapy promotes increased HbF production, thereby restoring functional hemoglobin levels.

Casgevy’s development was supported through the EMA’s PRIority MEdicines (PRIME) initiative, which offers early and enhanced scientific and regulatory assistance to medicines addressing critical unmet medical needs.

The recommendation from the Committee for Medicinal Products for Human Use (CHMP) marks an important milestone in Casgevy’s journey toward patient accessibility. This recommendation will now be forwarded to the European Commission for consideration in granting marketing authorization across the European Union. Subsequent decisions regarding pricing and reimbursement will be made at the discretion of individual Member States, taking into account the potential impact and utility of this therapy within their respective healthcare systems.1

For more information, please follow this link.

References

  1. First gene editing therapy to treat beta thalassemia and severe sickle cell disease | European Medicines Agency. (2023, December 15). https://www.ema.europa.eu/en/news/first-gene-editing-therapy-treat-beta-thalassemia-and-severe-sickle-cell-disease

Disclaimers

  • The material in these reviews is from various public open-access sources, meant for educational and informational purposes only
  • Any personal opinions expressed are those of only the author(s) and are not intended to represent the position of any organization(s)
  • No official support by any organization(s) has been provided or should be inferred